Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 280

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 280
---
.48)      |     | -0.5 (0.23) |     | -0.9, 0.0    |     |   0.035 |
| PainDETECT(3)                                                     |     | -2.7 (6.47)      |     | -2.5 (6.07)      |     | -0.3 (0.62) |     | -1.5, 0.9    |     |   0.642 |
| Brief Pain Inventory – Short Form score (pain severity)(2)        |     | -1.56 (1.952)    |     | -0.98 (1.928)    |     | -0.59       
 (0.200)     |     | -0.98, -0.20 |     |   0.003 |
| Brief Pain Inventory – Short Form score (pain interference)(3)    |     | -1.16 (2.413)    |     | -0.71 (2.095)    |     | -0.44       
 (0.221)     |     | -0.87, 0.00  |     |   0.049 |

| (1) | Baseline NPRS score is the mean of at least five days and no more than seven days of scores from the screening                                                                                       
 visit until treatment randomization. For the current pain, baseline is the last score prior to treatment. Baseline ODI is defined as the last ODI assessment score prior to the first dose on Day 1. |

| (2) | The analysis uses a REML-based MMRM with fixed effects for treatment                                 
 (SP-102 or placebo), week, site, Pain Catastrophizing Scale group (<30 or > 30), baseline score, and 
 treatment-by-week interaction.                                                                       |

191

| (3) | The analysis uses an ANCOVA model with fixed effects for treatment                             
 (SP-102 or placebo), site, Pain Catastrophizing Scale group (<30 or > 30), and baseline score. |

ANCOVA: analysis of covariance; ANOVA: analysis of variance; BPI-SF:Brief Pain Inventory – Short Form; CI: confidence interval; ITT: intent-to-treat(randomized population); LSM: least-squares mean; MMRM: mixed model for repeated measures; NPRS: numeric pain rating scale; RE